Insider Shareholders with Direct Ownership of An2 Therapeutics, Inc. (ANTX)
This section provides a comprehensive overview of the insiders with direct ownership of An2 Therapeutics, Inc. (ANTX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
AN2 Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 0 | 214,777 | 2,184,224 $2.77 Million | 11 |
Jun 06, 2022
Reduced 1.2%
|
|
| 135,015 | 0 | 135,015 $171,469 | 5 |
Dec 19, 2024
Added 6.78%
|
|
| 121,500 | 9,663 | 116,672 $148,173 | 4 |
Jan 03, 2025
Reduced 7.65%
|
|
|
Eric Easom
Chief Executive Officer |
103,907 | 97,008 | 101,130 $128,435 | 19 |
Mar 15, 2024
Added 49.47%
|
|
Paul Eckburg
Chief Medical Officer |
30,000 | 0 | 51,416 $65,298 | 1 |
Mar 15, 2024
Added 36.85%
|
|
Stephen David Prior
Chief Strategy Officer |
10,125 | 2,029 | 33,313 $42,307 | 2 |
Jan 03, 2025
Reduced 5.74%
|
|
Lucy Day
Chief Financial Officer |
27,500 | 2,957 | 32,670 $41,490 | 2 |
Jan 03, 2025
Reduced 8.3%
|
|
Kevin Michael Krause
Chief Strategy Officer |
40,000 | 10,000 | 31,914 $40,530 | 5 |
Mar 15, 2024
Added 48.45%
|
| 8,972 | 0 | 31,802 $40,388 | 1 |
Dec 19, 2024
Added 22.0%
|
|
|
Sanjay Chanda
Chief Development Officer |
27,500 | 2,957 | 29,824 $37,876 | 2 |
Jan 03, 2025
Reduced 9.02%
|
| 9,077 | 0 | 9,077 $11,527 | 1 |
Dec 19, 2024
Added 50.0%
|
|
| 8,972 | 0 | 8,972 $11,394 | 1 |
Dec 19, 2024
Added 50.0%
|
|
| 3,166 | 0 | 3,166 $4,020 | 1 |
Dec 19, 2024
Added 50.0%
|